Terns Pharmaceuticals Inc.

09/09/2024 | Press release | Distributed by Public on 09/09/2024 05:47

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN 601 Once Daily Oral GLP 1R Agonist for the Treatment of Obesity

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.